The FDA has extended its review period for Capricor Therapeutics' Duchenne muscular dystrophy cell therapy, creating uncertainty for the company. Meanwhile, the cancer vaccine developed by Merck and Moderna continues to demonstrate positive results.
FDA Extends Capricor DMD Therapy Review; Merck/Moderna Cancer Vaccine Shows Promise
|1 min read
biotechnologypharmaceuticalsFDA-reviewcancer-vaccineDMD-therapy
